New epilepsy drug aims to quiet brain storms in absence seizures
NCT ID NCT06769659
First seen Oct 31, 2025 · Last updated May 20, 2026 · Updated 25 times
Summary
This study tests an experimental drug called NPT 2042 in 10 people aged 16 to 75 with genetic generalized epilepsy and absence seizures. Each participant will receive both the drug and a placebo in random order, with a two-week break in between. The goal is to see if NPT 2042 can reduce how often and how long absence seizures occur, as measured by brain wave recordings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY, GENERALIZED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trials, Inc. (CTI)
RECRUITINGLittle Rock, Arkansas, 77205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.